Deal Maker of the Year Awards 2013 WINNER - JOHN BURT
DEAL: PolyTherics Limited merges with Antitope Limited’
NAME: John Burt COMPANY: PolyTherics Ltd WEBSITE:
www.polytherics.com
DEAL OVERVIEW Q
Please summarise the transaction In July 2013, PolyTherics executed
simultaneous financing and acquisition transactions in connection with the merger of the PolyTherics business with Cambridge- based pharmaceutical R&D service company, Antitope. PolyTherics issued £13.5 million of new equity in the financing round, which was led by Imperial Innovations and brought in new investors Invesco Perpetual alongside significant support from existing investors.
Q
What was your role within the transaction
As CEO of PolyTherics, I led both the financing and M&A processes from opportunity identification through to completion. Since the merger of PolyTherics and Antitope, I continue to lead the expanded group which now spans three sites in the UK in London, Cambridge and Coventry and providing services and technologies to pharmaceutical and biotechnology companies to enable the development of better biopharmaceuticals.
Q difficulties presented What were the challenges or
Managing parallel financing and M&A transactions and the associated teams of lawyers, corporate finance advisors and due diligence experts was a significant challenge, whilst at the same time, continuing to manage the core business.
56
www.finance-monthly.com
Having the support of my Chief Operating Officer, Sally Waterman, both on the transactional side and in continuing to manage the business ensured that all activities were well planned and executed. Excellent legal support from Field Fisher Waterhouse, with a deal team led by Bradley Theobald, ensured that the two corporate transaction processes remained aligned and moving to completion in an effective manner.
Q
How does the transaction fit in with your overall business strategy
PolyTherics is pursuing a two-prong growth strategy to establish itself as one of the leading providers of value-adding and proprietary services and technologies within the biopharmaceutical R&D sector. Combining organic growth through an expanded technology development, as exemplified by our ThioBridge technology for the creation of superior antibody-drug conjugates (ADCs) for cancer therapy, with the addition through M&A of additional service and technology offerings is driving a rapid growth in our top-line revenues as well as establishing critical mass for the business.
Q
What are your plans following the transaction
Integration of the PolyTherics and Antitope
UK
Q
How were the challenges or difficulties overcome
businesses is progressing extremely well and we are seeing the benefits of our broader service and technology offering leading to cross-selling opportunities with our target pharmaceutical and biotechnology company customers. We are not resting on our laurels and continue to drive the growth of the business along both growth paths. As we establish our position as a ‘one-stop shop’ for services and technologies in the biopharmaceutical sector and enjoy the support of our investors, which now runs from the institutional funds managed by Invesco Perpetual to high-net worth individual investors, we will continue to explore opportunities to continue the growth and enable our investors to enjoy a return on their investment.
What are your thoughts and predictions within your sector for 2014 and beyond
Q
The significant biotech IPO activity in the US will drive increased investor interest in this sector, but more risk-averse European investors will look for business models that provide significant potential upside but with a lower risk profile than has historically been demonstrated by UK and European biotech companies.
Whilst the economy moves towards a period of growth, cost pressures will continue to bear heavily on the pharmaceutical industry.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102